Oncotarget

Researchers discuss the discovery of a potential predictive biomarker for paclitaxel response in glioblastoma and breast cancer. Validation in patient cohorts and ongoing clinical trials are crucial for personalized medicine. Exploring new biomarkers is essential for improving therapeutic efficacy in conditions with variable treatment responses such as glioblastoma.

Exploring the rarity of NTRK gene fusion in thyroid cancer patients and the potential of TRK inhibitors as targeted therapies based on a clinicogenomic biobank study from Finland

Discover the latest research in oncology with Crossref's Top 10 Oncotarget papers of 2023, covering topics like angiogenesis inhibition in HNSCC, prognostic index for gastric cancer, crosstalk in triple negative breast cancer, and current approaches in systemic AL amyloidosis.

Exploring the genetic and therapeutic landscapes of pancreatic adenocarcinomas using next-generation sequencing and machine learning. Researchers delve into the heterogeneity and personalized treatment options for this deadly cancer.

The podcast delves into the investigation of Mad2 gene expression in human esophageal cancer, exploring its association with histone H3 modifications and chromosomal abnormalities. The potential of Mad2 as a clinical biomarker for esophageal carcinogenesis is discussed.

This podcast discusses genetic alterations in thyroid cancer that lead to resistance to BRF inhibitors and anaplastic transformation, highlighting the emergence of resistance mechanisms and the use of BRF inhibitors in combination with immune checkpoint inhibitors. The effectiveness of combined targeted therapy and immunomodulatory agents in enhancing anti-tumor immune activity and overcoming resistance in thyroid cancer patients is explored, along with ongoing clinical trials and the potential for personalized therapies.

Researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson discuss the role of Janus Kinase inhibitors in treating multiple myeloma, exploring their effectiveness in overcoming treatment resistance. They also delve into the studies on Ruxolitinib in preclinical and clinical settings for the treatment of relapsed refractory multiple myeloma.

Researchers from Devi Ahilya Vishwavidyalaya, Indore discuss the challenges and shortcomings in drug discovery in academia, including the time-consuming nature, lack of synergy between academia and industry, and reasons for therapeutic molecule failures.

Researchers discuss the role of BCAS1 in diffuse gliomas and its potential as a diagnostic and therapeutic target. The study reveals the heterogeneous cell population in different tumor samples, showcasing the unique features of BCAS1+ cells through immunostaining and electron microscopy.

In this podcast, researchers Mark Lee and Luc GT Morris discuss genetic alterations in thyroid cancer that mediate resistance to BRAF inhibition and anaplastic transformation. They explore the limited response to standard therapy in advanced-stage thyroid cancers. They also talk about the potential efficacy of dual-target therapies and the combination of targeted therapy with immunotherapy.